New study lets myasthenia gravis patients rate their own symptoms on a new drug
NCT ID NCT07570589
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 50 adults with generalized myasthenia gravis who are taking Rozanolixizumab. Researchers want to see how the drug affects symptoms like fatigue and muscle weakness from the patient's own point of view. Participants will fill out a special questionnaire over 9 months to track their experience. The goal is to better understand how well the treatment works in everyday life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de NICE
RECRUITINGNice, Alpes-maritimes, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••